Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers
Omalizumab remarkably affects inflammatory mediators in different pathways. CCL-3 and CCL-4 in serum and IgE, CXCL-1, GM-CSF, and IP-10 in nasal secretion may be considered as preferable biomarkers for predicting favorable or ineffective response to omalizumab therapy in patients with refractory CRSwNP comorbid with asthma, based on various clinical indicators.
Authors
- Yan Zhao (ORCID: https://orcid.org/0000-0002-9137-0247)
- Luo Zhang (ORCID: https://orcid.org/0000-0002-0910-9884)
- Chengyao Liu (ORCID: https://orcid.org/0000-0002-0056-9032)
- Yutong Sima
- Siqi Ge (ORCID: https://orcid.org/0000-0003-1030-6890)
- Xiangdong Wang (ORCID: https://orcid.org/0000-0002-0409-322X)
- Ping Wang (ORCID: https://orcid.org/0000-0001-7083-8632)
- Ming Zheng (ORCID: https://orcid.org/0000-0002-8991-6642)
Institutions
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Institute of Neurosurgery (CN)
- Beijing Municipal Education Commission (CN)
Publication Details
- Journal
- World Allergy Organization Journal
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1016/j.waojou.2024.101009
- Citations
- 4
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 2.32
Funders
- National Natural Science Foundation of China